Access to hepatitis C virus treatment: Lessons from implementation of strategies for increasing access to antiretroviral treatment
نویسندگان
چکیده
منابع مشابه
Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS.
The need to improve access to care and treatment for chronic hepatitis C virus (HCV) infection in resource-limited settings is receiving increasing attention. Key priorities for scaling up HCV treatment and care include reducing the cost of current and future treatment; simplifying the package of care; identifying opportunities to shift specific tasks to nonspecialists to overcome human resourc...
متن کاملHepatitis C virus treatment in the real world: optimising treatment and access to therapies.
Chronic HCV infections represent a major worldwide public health problem and are responsible for a large proportion of liver related deaths, mostly because of HCV-associated hepatocellular carcinoma and cirrhosis. The treatment of HCV has undergone a rapid and spectacular revolution. In the past 5 years, the launch of direct acting antiviral drugs has seen sustained virological response rates r...
متن کاملBarriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.
Restrictive policies on access to new, curative hepatitis C treatments represent a substantial barrier to treating patients infected with hepatitis C. This case series demonstrates challenges experienced by patients and practitioners in accessing these treatments and highlights several strategies for navigating the treatment preauthorization process.
متن کاملHepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy
Hepatitis C virus (HCV) infection remains a significant medical concern in the United States and around the world. It is still one of the leading causes of chronic liver disease, and, for more than 20 years, there has been little progress in the treatment of HCV infection. The advent of direct-acting antivirals (DAAs) initiated the era of high efficacy and well-tolerated medications with high c...
متن کاملLimited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs.
T burden of fatal liver disease is increasing in the estimated 3.2 million adults chronically infected with hepatitis C virus (HCV) in the United States (1–3). Sofosbuvir (Sovaldi, Gilead Sciences), which was approved by the U.S. Food and Drug Administration in December 2013, is a new oral HCV treatment that, when combined with other therapies, has a therapeutic efficacy (cure) greater than 90%...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Infectious Diseases
سال: 2018
ISSN: 1201-9712
DOI: 10.1016/j.ijid.2018.03.004